Kissin Eugene Y, Merkel Peter A, Lafyatis Robert
Boston University Medical Center, Boston, Massachusetts, USA.
Arthritis Rheum. 2006 Nov;54(11):3655-60. doi: 10.1002/art.22186.
To investigate the correlation between the degree of dermal fibrosis and myofibroblast infiltration using clinical assessments of skin thickness and hardness in systemic sclerosis (SSc).
Eleven patients with diffuse SSc and 10 healthy controls were evaluated using the modified Rodnan skin thickness score and durometry (hardness measurement). Biopsy samples were obtained from the dorsal mid-forearm in all subjects at the baseline visit and again 6-12 months later in patients with SSc. Five of the patients with SSc received treatment with cyclophosphamide (CYC) in the interval between skin biopsies. Biopsy sections were assessed for myofibroblast and hyalinized collagen content by 2 blinded observers.
Myofibroblast and hyalinized collagen scores each correlated with the forearm skin score (r = 0.83, P < 0.0001 and r = 0.78, P < 0.0001, respectively) and with the forearm durometry score (r = 0.72, P < 0.0004 and r = 0.69, P < 0.0008, respectively). The change in the dermal hyalinized collagen score correlated with the change in the forearm durometry score (r = 0.74, P < 0.0213). The myofibroblast score decreased in all 5 patients who received CYC and increased in those receiving non-CYC treatments (P < 0.01 for the difference).
Myofibroblasts play an important role in the pathogenesis of fibrosis, and our data imply that quantification of myofibroblasts and hyalinized collagen in skin may be a useful outcome measure in clinical studies of SSc.
通过对系统性硬化症(SSc)患者皮肤厚度和硬度的临床评估,研究真皮纤维化程度与肌成纤维细胞浸润之间的相关性。
使用改良的罗德南皮肤厚度评分和硬度计(硬度测量)对11例弥漫性SSc患者和10名健康对照者进行评估。在基线访视时从所有受试者的前臂背中部获取活检样本,SSc患者在6 - 12个月后再次获取。5例SSc患者在皮肤活检间隔期接受了环磷酰胺(CYC)治疗。由2名 blinded 观察者对活检切片的肌成纤维细胞和透明化胶原含量进行评估。
肌成纤维细胞和透明化胶原评分分别与前臂皮肤评分相关(r = 0.83,P < 0.0001和r = 0.78,P < 0.0001)以及与前臂硬度计评分相关(r = 0.72,P < 0.0004和r = 0.69,P < 0.0008)。真皮透明化胶原评分的变化与前臂硬度计评分的变化相关(r = 0.74,P < 0.0213)。接受CYC治疗的所有5例患者的肌成纤维细胞评分降低,而接受非CYC治疗的患者评分升高(差异P < 0.01)。
肌成纤维细胞在纤维化发病机制中起重要作用,我们的数据表明,在SSc临床研究中,对皮肤中肌成纤维细胞和透明化胶原进行定量可能是一种有用的疗效指标。